內源性血管生成抑制因子的研究進展及在肝癌中的應用前景_《中國普外基礎與臨床雜志》

作者：

鄧靖宇 , 何生

四川大學華西醫院普外科（成都610041）;

關鍵詞：

內源性血管生成抑制因子腫瘤內皮抑素血管抑素肝癌

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的介紹內源性血管生成抑制因子(內皮抑素、血管抑素)在肝癌治療中的作用和意義。
方法復習相關文獻資料并作綜述性報道。
結果內源性血管生成抑制因子通過抑制腫瘤血管的生長，有效地阻礙了肝癌的發展和轉移，可為臨床肝癌治療提供新的途徑。
結論應用內源性血管生成抑制因子的研究,對肝癌的防治將有積極的意義。

引用本文： 鄧靖宇,何生. 內源性血管生成抑制因子的研究進展及在肝癌中的應用前景. 中國普外基礎與臨床雜志, 2006, 13(2): 184-186. doi: 復制

1.	Folkman J. Tumor angiogenesis: therapeutic implications [J]. N Engl J Med, 1971; 285(21)∶1182.
2.	Yancopoulos GD, Davis S, Gale NW, et al. Vascularspecific growth factors and blood vessel formation [J]. Nature, 2000; 407(6801)∶242.
3.	Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J]. Cell, 1996; 86(3)∶353.
4.	Iwasaki T, Hamano T, Ogata A, et al. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma [J]. Br J Haematol, 2002; 116(4)∶796.
5.	侯恩存. 腫瘤血管生成與抗血管生成治療 [J]. 中國腫瘤臨床與康復， 2003； 10（2）∶179.
6.	過邦輔，凌勵立. 血管生成和蛋白酶在腫瘤侵襲中的作用 [J]. 中國腫瘤， 1999； 8（4）∶177.
7.	王成偉，寵琦，張慶林. 血管生成與腫瘤的生長及轉移 [J]. 國外醫學·腫瘤學分冊， 2001； 28（2）∶118.
8.	Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease [J]. Nat Med, 1995; 1(1)∶27.
9.	駱成玉，祝學光. 腫瘤血管生成對微轉移影響的研究進展 [J]. 中國普外基礎與臨床雜志， 2003； 10（5）∶516.
10.	Thaloor D, Singh AK, Sidhu GS, et al. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin [J]. Cell Growth Differ, 1998; 9(4)∶305.
11.	Folkman J. What is the evidence that tumors are angiogenesis dependent? [J]. J Natl Cancer Inst, 1990; 82(1)∶4.
12.	顏春洪，韓銳. 抗惡性腫瘤轉移藥研究進展 [A]. 見：曹世龍主編.腫瘤學新理論與新技術 [M]. 上海：上海科技教育出版社， 1997∶462～484.
13.	Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis [J]. Cancer Metastasis Rev, 1996; 15(2)∶165.
14.	Merwin RM, Algire GH. The role of graft and host vessels in the vascularization of grafts of normal and neoplastic tissue [J]. J Natl Cancer Inst, 1956; 17(1)∶23.
15.	Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis [J]. Nature, 1982; 297(5864)∶307.
16.	后信，桑野信彥. か轉移阻止開發口一千 [J]. 日本癌癥治療， 1995； 30（5）∶713.
17.	Saphir A. Angiogenesis: the unifying concept in cancer? [J]. J Natl Cancer Inst, 1997; 89(22)∶1658.
18.	Burke PA, DeNardo SJ. Antiangiogenic agents and their promising potential in combined therapy [J]. Crit Rev Oncol Hematol, 2001; 39(1-2)∶155.
19.	王貴齊. 腫瘤與血管 [J]. 中國腫瘤臨床， 1995； 22（10）∶743.
20.	Cao Y, Ji RW, Davidson D, et al. Kringle domains of human angiostatin. Characterization of the antiproliferative activity on endothelial cells [J]. J Biol Chem, 1996; 271(46)∶29461.
21.	Cao Y, Chen A, An SS, et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth [J]. J Biol Chem, 1997; 272(36)∶22924.
22.	Luo J, Lin J, Paranya G, et al. Angiostatin upregulates Eselectin in proliferating endothelial cells [J]. Biochem Biophys Res Commun, 1998; 245(3)∶906.
23.	Ito H, Rovira II, Bloom ML, et al. Endothelial progenitor cells as putative targets for angiostatin [J]. Cancer Res, 1999; 59(23)∶5875.
24.	Standker L, Schrader M, Kanse SM, et al. Isolation and characterization of the circulating form of human endostatin [J]. FEBS Lett, 1997; 420(2-3)∶129.
25.	Schuppan D, Cramer T, Bauer M, et al. Hepatocytes as a source of collagen type ⅩⅧ endostatin [J]. Lancet, 1998; 352(9131)∶879.
26.	He ZY, Chen ZY, Qiu CP, et al. Cloning, expression and tamor suppression of human endostatin [J]. Acta Biochemica and Biophysica Sinica, 2000; 32(4)∶333.
27.	Felbor U, Dreier L, Bryant RA, et al. Secreted cathepsin L generates endostatin from collagen ⅩⅧ [J]. EMBO J, 2000; 19(6)∶1187.
28.	王軒，劉福坤，黎介壽. 血管內皮抑制素的研究進展 [J]. 臨床腫瘤學雜志， 2001； 6（3）∶287.
29.	Dixelius J, Larsson H, Sasaki T, et al. Endostatininduced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis [J]. Blood, 2000; 95(11)∶3403.
30.	Yamaguchi N, AnandApte B, Lee M, et al. Endostatin inhibits VEGFinduced endothelial cell migration and tumor growth independently of zinc binding [J]. EMBO J, 1999; 18(16)∶4414.
31.	Dhanabal M, Volk R, Ramchandran R, et al. Cloning, expression, and in vitro activity of human endostatin [J]. Biochem Biophys Res Commun, 1999; 258(2)∶345.
32.	Hohenester E, Sasaki T, Mann K, et al. Variable zinc coordination in endostatin [J]. J Mol Biol, 2000; 297(1)∶1.
33.	Perletti G, Concari P, Giardini R, et al. Antitumor activity of endostatin against carcinogeninduced rat primary mammary tumors [J]. Cancer Res, 2000; 60(7)∶1793.
34.	孫惠川，湯釗猷，王魯. Endostatin抑制裸鼠移植性肝癌切除后的復發移植 [J]. 中華腫瘤雜志， 2000； 22（6）∶469.
35.	Folkman J. Antiangiogenic gene therapy [J]. Proc Natl Acad Sci USA， 1998; 95(16)∶9064.
36.	Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP470 alone and with other antiangiogenic agents [J]. Int J Cancer, 1994; 57(6)∶920.

1. Folkman J. Tumor angiogenesis: therapeutic implications [J]. N Engl J Med, 1971; 285(21)∶1182.
2. Yancopoulos GD, Davis S, Gale NW, et al. Vascularspecific growth factors and blood vessel formation [J]. Nature, 2000; 407(6801)∶242.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J]. Cell, 1996; 86(3)∶353.
4. Iwasaki T, Hamano T, Ogata A, et al. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma [J]. Br J Haematol, 2002; 116(4)∶796.
5. 侯恩存. 腫瘤血管生成與抗血管生成治療 [J]. 中國腫瘤臨床與康復， 2003； 10（2）∶179.
6. 過邦輔，凌勵立. 血管生成和蛋白酶在腫瘤侵襲中的作用 [J]. 中國腫瘤， 1999； 8（4）∶177.
7. 王成偉，寵琦，張慶林. 血管生成與腫瘤的生長及轉移 [J]. 國外醫學·腫瘤學分冊， 2001； 28（2）∶118.
8. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease [J]. Nat Med, 1995; 1(1)∶27.
9. 駱成玉，祝學光. 腫瘤血管生成對微轉移影響的研究進展 [J]. 中國普外基礎與臨床雜志， 2003； 10（5）∶516.
10. Thaloor D, Singh AK, Sidhu GS, et al. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin [J]. Cell Growth Differ, 1998; 9(4)∶305.
11. Folkman J. What is the evidence that tumors are angiogenesis dependent? [J]. J Natl Cancer Inst, 1990; 82(1)∶4.
12. 顏春洪，韓銳. 抗惡性腫瘤轉移藥研究進展 [A]. 見：曹世龍主編.腫瘤學新理論與新技術 [M]. 上海：上海科技教育出版社， 1997∶462～484.
13. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis [J]. Cancer Metastasis Rev, 1996; 15(2)∶165.
14. Merwin RM, Algire GH. The role of graft and host vessels in the vascularization of grafts of normal and neoplastic tissue [J]. J Natl Cancer Inst, 1956; 17(1)∶23.
15. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis [J]. Nature, 1982; 297(5864)∶307.
16. 后信，桑野信彥. か轉移阻止開發口一千 [J]. 日本癌癥治療， 1995； 30（5）∶713.
17. Saphir A. Angiogenesis: the unifying concept in cancer? [J]. J Natl Cancer Inst, 1997; 89(22)∶1658.
18. Burke PA, DeNardo SJ. Antiangiogenic agents and their promising potential in combined therapy [J]. Crit Rev Oncol Hematol, 2001; 39(1-2)∶155.
19. 王貴齊. 腫瘤與血管 [J]. 中國腫瘤臨床， 1995； 22（10）∶743.
20. Cao Y, Ji RW, Davidson D, et al. Kringle domains of human angiostatin. Characterization of the antiproliferative activity on endothelial cells [J]. J Biol Chem, 1996; 271(46)∶29461.
21. Cao Y, Chen A, An SS, et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth [J]. J Biol Chem, 1997; 272(36)∶22924.
22. Luo J, Lin J, Paranya G, et al. Angiostatin upregulates Eselectin in proliferating endothelial cells [J]. Biochem Biophys Res Commun, 1998; 245(3)∶906.
23. Ito H, Rovira II, Bloom ML, et al. Endothelial progenitor cells as putative targets for angiostatin [J]. Cancer Res, 1999; 59(23)∶5875.
24. Standker L, Schrader M, Kanse SM, et al. Isolation and characterization of the circulating form of human endostatin [J]. FEBS Lett, 1997; 420(2-3)∶129.
25. Schuppan D, Cramer T, Bauer M, et al. Hepatocytes as a source of collagen type ⅩⅧ endostatin [J]. Lancet, 1998; 352(9131)∶879.
26. He ZY, Chen ZY, Qiu CP, et al. Cloning, expression and tamor suppression of human endostatin [J]. Acta Biochemica and Biophysica Sinica, 2000; 32(4)∶333.
27. Felbor U, Dreier L, Bryant RA, et al. Secreted cathepsin L generates endostatin from collagen ⅩⅧ [J]. EMBO J, 2000; 19(6)∶1187.
28. 王軒，劉福坤，黎介壽. 血管內皮抑制素的研究進展 [J]. 臨床腫瘤學雜志， 2001； 6（3）∶287.
29. Dixelius J, Larsson H, Sasaki T, et al. Endostatininduced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis [J]. Blood, 2000; 95(11)∶3403.
30. Yamaguchi N, AnandApte B, Lee M, et al. Endostatin inhibits VEGFinduced endothelial cell migration and tumor growth independently of zinc binding [J]. EMBO J, 1999; 18(16)∶4414.
31. Dhanabal M, Volk R, Ramchandran R, et al. Cloning, expression, and in vitro activity of human endostatin [J]. Biochem Biophys Res Commun, 1999; 258(2)∶345.
32. Hohenester E, Sasaki T, Mann K, et al. Variable zinc coordination in endostatin [J]. J Mol Biol, 2000; 297(1)∶1.
33. Perletti G, Concari P, Giardini R, et al. Antitumor activity of endostatin against carcinogeninduced rat primary mammary tumors [J]. Cancer Res, 2000; 60(7)∶1793.
34. 孫惠川，湯釗猷，王魯. Endostatin抑制裸鼠移植性肝癌切除后的復發移植 [J]. 中華腫瘤雜志， 2000； 22（6）∶469.
35. Folkman J. Antiangiogenic gene therapy [J]. Proc Natl Acad Sci USA， 1998; 95(16)∶9064.
36. Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP470 alone and with other antiangiogenic agents [J]. Int J Cancer, 1994; 57(6)∶920.

《中國普外基礎與臨床雜志》

內源性血管生成抑制因子的研究進展及在肝癌中的應用前景

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

內源性血管生成抑制因子的研究進展及在肝癌中的應用前景

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料